Dr. Sushant Mittal
Dr. Sushant Mittal is one of the most vibrant & enthusiastic oncologists of the country. A confident oncologist, he reflects the culture of Tata Memorial hospital, where he achieved finesse in management of patients with internationally acclaimed protocols.
His research in many specific fields of Oncology like Hodgkin's lymphoma has greatly improved the patient outcome.
He has trained & taught many post graduate students & nurses to improve the patient care. With the same enthusiasm & dynamicity, he has been working in Delhi NCR.
A hard worker with a positive attitude towards the sick, he deals with all kinds of cancer. He has a passion for cure & control of cancer which make him an exceptional
oncologist. His motto is to provide comprehensive & holistic treatment to each & every cancer patient.
He has numerous national & international publications to his credit. As a medical oncologist, Dr. Mittal collaborates closely with other healthcare professionals, including surgeons, radiation oncologists, and supportive care specialists, to develop comprehensive treatment plans tailored to each patient's unique needs.
Work Experience: 16+ years
- Senior Residency (Internal Medicine) at Sri Ganga Ram Hospital, Delhi: July 2008 to May 2009
- Senior Residency (Medical Oncology) at IRCH, AIIMS, Delhi: June 2009 to July 2010
- DM Medical Oncology at Tata Memorial Centre, Mumbai: August 2010 to July 2013
- Associate consultant at Fortis Memorial Research Centre, Gurgaon: August 2013 to September 2014
- Consultant in Artemis Health Institute, Gurgaon: September 2014 to December 2016
- Director, at Action Cancer Hospital, Delhi: January 2017 to till date
Research & Publication
- Department of Medical Oncology
Tata Memorial Centre, Mumbai
Utility of PET scan in preclinical diagnosis of Bleomycin induced lung toxicity in Hodgkin Lymphoma patients (DM thesis)) (accepted for Poster Presentation at ESMO 2013, Amsterdam to be held in September2013
Role: Chief Investigator
- Department of Medical Oncology
Tata Memorial Centre, Mumbai
Retrospective analysis of primary CNS lymphoma patients at Tata Memorial Center.
Role: Chief Investigator
- Incidence of gastro intestinal manifestations in HIV positive patients (MD thesis)
- TZ-01-002: A Randomized, Double-Blind, Multicentre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in combination with weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2- Positive Metastatic Breast Cancer” as Co PI
- SB3-G31-BC: “A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting”. as Co PI
- A multicentre, randomized, open label, two period, two treatment, two way crossover, comparative bioavailability study at Steady state comparing Capecitabine Extended release Capsule 500mg (Intas Pharmaceuticals Ltd, India) to the reference listed drug Xeloda (Capecitabine 500mg ; Roche Pharmaceuticals) in patients of Breast Cancer or Colorectal cancer under fed condition as Co PI
- A Phase III randomized, open- label, Multi-center, global study of MEDI4736 alone or in combination with Tremelimumab versus standard of Care in the treatment of First-line recurrent or Metastatic Squamous Cell Head & neck cancer patients. as PI
- A multicenter, open label, balanced, randomized, two treatment, three period, three sequence, reference replicate crossover, single dose, oral bioequivalence study of Capecitabine film coated tablets 500mg of Shilpa Medicare Limited, India & Xeloda film coated tablets 500mg (Capecitabine) marketed by Roche Registration limited, 6 Falcon way, Shire park, Welwyn garden city, AL71 TW United Kingdome following single oral dose of 2000mg (4x500mg) in adult human cancer patients under fed conditions as Co PI
- A Phase III randomized, open- label, Multi-center, global study of MEDI4736 alone or in combination with Tremelimumab versus standard of Care in the treatment of Metastatic Lung cancer as PI
- A Randomized, Open-Label, Multi-Center Phase III Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA) as PI
- A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center,
- International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) as PI
- An open label, observational, multicentric, prospective, single arm, drug utilization surveillance study to evaluate safety and efficacy of Abiraterone acetate in chemonaive patients with metastatic prostate cancer as Co PI
- An active surveillance to monitor the real world safety in Indian patients prescribed nintedanib for the treatment of locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Director
MBBS, MD, DM
Medical Oncology & Hematology (AIIMS, Delhi, Tata Memorial, Mumbai
Action Cancer Hospital
16+ years of Experience
Speciality Interest
Preventive Health
Contact Us